Outcome With Calcium Channel Antagonists After Myocardial Infarction: A Community-Based Study  by Leitch, James W et al.
Outcome With Calcium Channel Antagonists After Myocardial
Infarction: A Community-Based Study
JAMES W. LEITCH, MBBS, PATRICK MCELDUFF, BMATH,* ANNETTE DOBSON, PHD,†
RICHARD HELLER, MBBS, MD*
Newcastle, New South Wales, Australia
Objectives. We sought to estimate the risk of death and
recurrent myocardial infarction associated with the use of calcium
antagonists after myocardial infarction in a population-based
cohort study.
Background. Calcium antagonists are commonly prescribed
after myocardial infarction, but their long-term effects are not well
established.
Methods. Patients 25 to 69 years old with a suspected myocar-
dial infarction were identified and followed up through a
community-based register of myocardial infarction and cardiac
death (part of the World Health Organization Monitoring Trends
and Determinants in Cardiovascular Disease [MONICA] Project
in Newcastle, Australia). Data were collected by review of medical
records, in-hospital interview and review of death certificates.
Results. From 1989 to 1993, 3,982 patients with a nonfatal
suspected myocardial infarction were enrolled in the study. At
hospital discharge, 1,001 patients were treated with beta-
adrenergic blocking agents, 923 with calcium antagonists, 711
with both beta-blockers and calcium antagonists and 1,346 with
neither drug. Compared with patients given beta-blockers, pa-
tients given calcium antagonists were more likely to suffer myo-
cardial infarction or cardiac death (adjusted relative risk [RR]
1.4, 95% confidence interval [CI] 1.0 to 1.9), cardiac death (RR
1.6, 95% CI 1.0 to 2.7) and death from all causes (RR 1.7, 95% CI
1.1 to 2.6). Compared with patients given neither beta-blockers
nor calcium antagonists, patients given calcium antagonists were
not at increased risk of myocardial infarction or cardiac death
(RR 1.0, 95% CI 0.8 to 1.3), cardiac death (RR 0.9, 95% CI 0.6 to
1.2) or death from all causes (RR 1.0, 95% CI 0.7 to 1.3). No excess
in risk of myocardial infarction or cardiac death was observed
among patients taking verapamil (RR 0.9, 95% CI 0.6 to 1.6),
diltiazem (RR 1.1, 95% CI 0.8 to 1.4) or nifedipine (RR 1.3, 95% CI
0.7 to 2.2) compared with patients taking neither calcium antag-
onists nor beta-blockers.
Conclusions. These results are consistent with randomized trial
data showing benefit from beta-blockers after myocardial infarc-
tion and no effect on the risk of recurrent myocardial infarction
and death with the use of calcium antagonists. Comparisons
between beta-blockers and calcium antagonists favor beta-
blockers because of the beneficial effects of beta-blockers and not
because of adverse effects of calcium antagonists.
(J Am Coll Cardiol 1998;31:111–7)
©1998 by the American College of Cardiology
Calcium antagonists are effective treatment for symptoms of
angina and for control of hypertension (1–5), but there is little
evidence that calcium antagonists decrease mortality or pre-
vent myocardial infarction. In general, studies of routine use of
calcium antagonists after myocardial infarction have not shown
a mortality benefit (6–13). Several trials of dihydropyridine
calcium antagonists raised concerns that this class of calcium
antagonists may be harmful in patients with severe ischemia
(14–17), and a recent meta-analysis reported increased mor-
tality with the use of nifedipine for secondary prevention
(18–20). Despite lack of evidence of reduction in the risk of
death, there has been increasing use of calcium antagonists in
the Australian community, whereas the use of beta-adrenergic
blocking agents, which have proven beneficial effects on mor-
tality, has declined (McManus P, Drug Utilisation Sub Com-
mittee, Australian Pharmaceutical Benefits Advisory Commit-
tee, personal communication, July 1996), (21). Similar trends
in the use of calcium antagonists have been noted elsewhere (22).
The Monitoring Trends and Determinants in Cardiovascu-
lar Disease (MONICA) Project is a World Health Organiza-
tion (WHO) coordinated study monitoring international
trends and determinants in cardiovascular disease (23). A large
cohort of patients with a suspected myocardial infarction were
studied by the collaborating center in Newcastle, Australia.
This study provided the opportunity to compare outcomes
among patients treated with calcium antagonists and beta-
blockers after myocardial infarction in a community-based
setting. We hypothesized that calcium antagonist use would be
associated with adverse outcome compared with treatment
with beta-blockers.
From the Department of Medicine, John Hunter Hospital; *Centre for
Clinical Epidemiology and Biostatistics; and †Department of Statistics, Univer-
sity of Newcastle, Newcastle, New South Wales, Australia. The Newcastle
Collaborating Centre for the WHO MONICA Project was supported by the
National Health and Research Council of Australia and National Heart Foun-
dation of Australia, Canberra.
Manuscript received May 12, 1997; revised manuscript received July 14,
1997, accepted October 2, 1997.
Address for correspondence: Dr. James W. Leitch, Department of Cardiol-
ogy, John Hunter Hospital, Locked Bag 1, Hunter Region Mail Centre,
Newcastle, New South Wales, 2310, Australia. E-mail: jleitch@ozemail.com.au.
JACC Vol. 31, No. 1
January 1998:111–7
111
©1998 by the American College of Cardiology 0735-1097/98/$19.00
Published by Elsevier Science Inc. PII S0735-1097(97)00445-2
Methods
Study protocol. The Newcastle collaborating center of the
WHO MONICA Project monitored all suspected cases of
sudden coronary death and acute myocardial infarction among
residents of the Lower Hunter region of New South Wales who
were aged 25 to 69 years old. Study nurses monitored all
hospitals in the area, registering every patient likely to meet
the study criteria. Patients were interviewed while in the
hospital to obtain information on symptoms, medical history
and smoking status. Cardiac enzyme results were extracted
from hospital records, and electrocardiograms (ECGs) were
copied and subsequently coded according to the Minnesota
code (23). Enzyme levels were reported as a percentage of the
upper limit of the normal range for the relevant laboratory.
For this study, ECG results were classified according to
categories used in the definition of the Norris index (24).
Details of medication use during the event and at discharge
were obtained from the medical record. Medication dosage
and formulation were not recorded. All death certificates for
the cohort were also scrutinized. Details of fatal cases were
obtained from the death certificates and postmortem records
and from questionnaires sent to doctors, relatives and other
informants. The study had ethics approval from the public
hospitals in the region and from the University of Newcastle
Research Ethics Committee.
Event classification. The cardiac events reported here
were those satisfying the criteria for definite or possible
myocardial infarction and cardiac death used in the WHO
MONICA Project (23,25). These definitions are summarized
as follows: Definite myocardial infarction was defined by either
unequivocal serial ECG progression (defined by Minnesota
codes) during the attack or by cardiac enzyme levels twice the
level of normal and specific combinations of symptoms and
ECG changes. Possible myocardial infarction was defined as
typical prolonged (20 min) chest pain with ECG and enzyme
changes not fulfilling the criteria for definite myocardial infarc-
tion and with no other cause for the symptoms established.
Therefore, in some nonfatal cases, this definition was consis-
tent with a clinical diagnosis of unstable angina; for others, a
clinical diagnosis of myocardial infarction was probable (26).
Classification of fatal events. Fatal events were classified as
definite myocardial infarction if they satisfied the criteria for
nonfatal definite myocardial infarction or if autopsy data
confirmed acute myocardial infarction. Fatal cases with sug-
gestive terminal symptoms, a history of coronary artery disease
or autopsy evidence of chronic occlusive coronary disease
without another cause of death established were classified as
possible myocardial infarction. Patients who died shortly after
the onset of symptoms of myocardial infarction were usually
classified as having a possible myocardial infarction because
serial measurements of ECG and enzymes were not possible.
Some cardiac deaths were unclassifiable if the cause of death
on the death certificate was coded 410–414 according to the
International Classification of Disease, 9th Revision, but infor-
mation required for the other MONICA criteria was lacking.
For this study, events categorized as fatal, possible or definite
myocardial infarction or unclassifiable cardiac death were
grouped together as cardiac death.
Patients and outcomes. This study involved patients who
survived at least 28 days from the onset of symptoms of a
definite or possible myocardial infarction between September
1988 and December 1993. The main outcome of interest was
the time to the next major coronary event, defined as possible or
definite myocardial infarction or cardiac death. We also exam-
ined as separate outcomes the times to definite myocardial
infarction or cardiac death, cardiac death and all-cause mor-
tality.
Subjects were deemed to have had another major coronary
event if they were registered by the MONICA Project on a
second occasion before March 31, 1994 and satisfied the
diagnostic criteria outlined above. The MONICA register only
collected information for people between 25 and 69 years old;
therefore, as subjects turned 70, they were censored.
Statistical analysis. Chi-square tests were used to compare
patient groups defined by the use of beta-blocker and calcium
antagonist therapy at discharge. Relative risk estimates were
calculated using survival analysis techniques (27). Accelerated
failure time models that assumed the probability of having
another major coronary event and followed a Weibull distri-
bution were used. These models are equivalent to parametric
proportional hazards models (28). Adjustment was made for
the possible confounding effects of age (5-year age groups);
gender; history of hypertension; hypercholesterolemia; diabe-
tes; previous myocardial infarction; angina and stroke; smok-
ing status (current, previous or never); peak creatine kinase
level; ECG classification; use of frusemide or digoxin, or both,
in the hospital; use of aspirin; angiotensin-converting enzyme
inhibitors; diuretic drugs; digoxin; antiarrhythmic and bron-
chodilator medication at discharge from hospital; and year of
enrollment. There were 12 patients with missing ECG infor-
mation and 14 with missing enzyme data for the initial event:
For the multivariate analysis, these patients were included by
creating separate categories for missing data. The analysis was
repeated after exclusion of patients with missing data, with
only trivial effects on the results.
The initial analysis was performed with all patients who had
a definite or possible myocardial infarction. A separate analysis
was performed restricting the cohort to patients with definite
myocardial infarction as the first registered event. In these
analyses, the reference group was patients discharged with
beta-blockers but not calcium antagonists. To evaluate the
Abbreviations and Acronyms
CI 5 confidence interval
ECG 5 electrocardiogram, electrocardiographic
MONICA 5 Monitoring Trends and Determinants in Cardiovascular
Disease
RR 5 relative risk
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risks associated with the use of individual calcium antagonists,
analyses were performed with patients given neither calcium
antagonists nor beta-blockers as the reference group. For each
of these analyses, the outcome variables were times to another
major coronary event; definite myocardial infarction or cardiac
death, or both; cardiac death; and all-cause mortality. When a
patient satisfied the criteria for more than one outcome, the
time to the first relevant outcome was used. For example, for
a patient with recurrent myocardial infarction who later died
during a further myocardial infarction, the time to the first
recurrent myocardial infarction would be used in the analysis
of major coronary events and the time to death in the analyses
of cardiac and all-cause mortality.
Results
Patients. There were 1,001 patients treated with beta-
blockers, 923 with calcium antagonists, 711 with both beta-
blockers and calcium antagonists and 1,346 with neither drug
at the time of hospital discharge after a definite or possible
myocardial infarction during the study period. The median
observation time was 664 days (interquartile range 226 to
1,227), with a total observation period of 8,430 person-years.
Baseline characteristics. There were substantial differ-
ences in baseline characteristics of patients according to the
use of beta-blockers and calcium antagonists at the time of
hospital discharge (Table 1). Compared with patients treated
with beta-blockers, patients treated with calcium antagonists
were older, were more likely to have angina and were treated
more frequently with diuretic drugs, digoxin, angiotensin-
converting enzyme inhibitors and bronchodilators. The differ-
ences between patients treated with beta-blockers and those
treated with neither beta-blockers nor calcium antagonists
were smaller, except for the prevalence of hypertension and
the use of aspirin (which were more common in patients
treated with beta-blockers) and the use of diuretic drugs,
digoxin and bronchodilators (which were more prevalent in
patients given neither beta-blockers nor calcium antagonists).
Risk of major coronary events. The results from the sur-
vival analysis are shown in Table 2. In total, there were 493
nonfatal possible myocardial infarctions, 247 nonfatal definite
myocardial infarctions, 211 cardiac deaths and 406 deaths from
all causes (including cardiac deaths) in the study participants.
When adjusted for all covariates, there was an increased risk of
another major coronary event for subjects treated with calcium
antagonists compared with those treated with beta-blockers
(adjusted relative risk [RR] 1.5, 95% confidence interval [CI]
1.2 to 1.9). Relative risks for the outcomes of definite myocar-
dial infarction or cardiac death (1.4, 95% CI 0.98 to 1.9),
cardiac death (1.6, 95% CI 0.97 to 2.7) and all-cause mortality
(1.7, 95% CI 1.1 to 2.6) were also higher for this patient group.
Patients treated with neither beta-blockers nor calcium
antagonists were also at increased risk of recurrent definite
myocardial infarction or cardiac death (RR 1.4, 95% CI 1.0 to
1.9), cardiac death (RR 2.0, 95% CI 1.2 to 3.3) and all-cause
mortality (RR 1.8, 95% CI 1.2 to 2.8) compared with patients
treated with beta-blockers.
Results in patients with a definite myocardial infarction.
Relative risks were slightly but consistently higher when the
analysis was restricted to the 1,855 patients with a definite
myocardial infarction as the initial registered event. In this
cohort, the adjusted relative risk of recurrent myocardial
infarction or cardiac death was 1.5 (95% CI 1.0 to 2.3), cardiac
death 2.0 (95% CI 1.1 to 3.95) and all-cause mortality 1.9 (95%
CI 1.1 to 3.4) for patients taking calcium antagonists compared
with patients taking beta-blockers.
Patients treated with both beta-blockers and calcium an-
tagonists. Patients treated with both beta-blockers and cal-
cium antagonists were at increased risk of a major coronary
event (RR 1.6, 95% CI 1.3 to 2.0) compared with patients
treated with beta-blockers only. For the outcomes of cardiac
death and death by all causes, patients taking both beta-
blockers and calcium antagonists had risks that were interme-
diate between those treated with calcium antagonists and those
treated with beta-blockers, and the confidence intervals in-
cluded unity (Table 2).
Verapamil, diltiazem and nifedipine. The major calcium
antagonists prescribed were verapamil (185 patients), dilti-
azem (596 patients) and nifedipine (100 patients). Compared
with patients given neither beta-blockers nor calcium antago-
nists, patients given diltiazem (RR 1.4, 95% CI 1.2 to 1.8) and
nifedipine (RR 1.7, 95% CI 1.1 to 2.5) were at increased risk of
another coronary event (Table 3). Most of the increased risk of
recurrent events in these patients was attributable to an
increased risk of nonfatal possible myocardial infarction. For
the other outcomes of definite myocardial infarction or cardiac
death, cardiac death and all-cause mortality, results were
similar among the patients treated with different calcium
antagonists and were not significantly different from patients
treated with neither agent.
Discussion
There is a need for large population-based studies of drug
use and outcomes in the community to complement the data
from selected patients in controlled conditions (29). Random-
ized trials show that beta-blocker therapy after myocardial
infarction reduces the risk of death and recurrent myocardial
infarction by ;25% (30). In contrast, trials of calcium antag-
onists after myocardial infarction have generally shown a
neutral effect on these outcomes (8,11,12). The results of the
present community-based cohort study are concordant with the
randomized trial data and demonstrate an improved outcome
with the use of beta-blockers versus calcium antagonist ther-
apy.
Adverse effects of calcium antagonists. The role of calcium
antagonists is currently unsettled because of lack of long-term
data about the effects of these drugs on mortality and recent
observational studies demonstrating an increased risk of ad-
verse events, including recurrent myocardial infarction (31),
gastrointestinal hemorrhage (32) and cancer (33). The results
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of the present study do not support a major increase in risk of
adverse events from the use of calcium antagonists after
myocardial infarction. Increased mortality among patients
given calcium antagonists was observed only in comparison to
a reference group given beta-blockers, indicating that the
difference between the groups was due to the beneficial effect
of beta-blockers rather than an adverse effect of calcium
antagonists. The results of the present study are consistent with
another community-based study of beta-blocker and calcium
antagonist use after myocardial infarction (34). In that study,
Table 1. Patient Characteristics According to Use of Calcium Antagonist and Beta-Adrenergic














25–54 37% 37% 24% 28% , 0.001
55–64 37% 39% 42% 45%
65–69 26% 24% 34% 27%
Men 69% 72% 65% 67% 0.010
Diabetes 11% 9% 15% 12% , 0.001
Angina 20% 21% 47% 54% , 0.001
Previous MI 22% 23% 13% 12% , 0.001
Stroke 6% 5% 8% 7% 0.024
High blood pressure 39% 51% 53% 63% , 0.001
High cholesterol 35% 43% 43% 49% , 0.001
Smoking status
Current 39% 35% 31% 24% , 0.001
Ex-smoker 31% 31% 36% 38%
Never-smoker 30% 34% 32% 38%
Other drug use
Aspirin 55% 78% 62% 72% , 0.001
ACE inhibitor 26% 17% 24% 18% , 0.001
Antiarrhythmic 5% 1% 3% 1% , 0.001
Diuretic drugs 22% 10% 27% 16% , 0.001
Digoxin 18% 6% 16% 5% , 0.001
Bronchodilators 16% 2% 16% 3% , 0.001
CK (% of normal)
0–100 42% 37% 56% 61% , 0.001
101–500 28% 33% 29% 27%
501–1,000 13% 15% 9% 7%
1,001–2,000 12% 11% 4% 3%
2,0011 4% 4% 1% 1%
Not measured 1% 0% 1% 1%
Unknown 1% 0% 0% 0%
ECG classification
Ant non-Q wave 11% 14% 13% 12% , 0.001
Ant Q wave 3% 2% 3% 3%
LBBB 12% 10% 7% 6%
No changes 21% 17% 18% 20%
Post non-Q wave 1% 0% 2% 1%
Post Q wave 38% 44% 47% 48%
Unclassifiable 13% 12% 9% 10%
Unknown 0% 0% 0% 0%
Year of MI onset
1988 8% 6% 6% 8% , 0.001
1989 23% 19% 20% 18%
1990 21% 18% 19% 21%
1991 17% 18% 21% 15%
1992 15% 19% 16% 19%
1993 15% 21% 19% 19%
Data presented are percent of patients. ACE 5 angiotensin-converting enzyme; CK 5 creatine kinase; ECG 5
electrocardiographic; LBBB 5 left bundle branch block; MI 5 myocardial infarction.
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the use of a calcium antagonist instead of a beta-blocker after
myocardial infarction was associated with an adjusted relative
risk of death of 1.98 (95% CI 1.44 to 2.72). In the present
study, the risk estimate for the same comparison, in patients
with definite myocardial infarction, was 1.90 (95% CI 1.05 to
3.41).
Verapamil, diltiazem and nifedipine. The risks of definite
myocardial infarction and death were not significantly different
among patients given verapamil, diltiazem and nifedipine
(Table 3), with risk estimates all close to 1 compared with
patients taking neither beta-blockers nor calcium antagonists.
However, in patients given nifedipine or diltiazem, there was
an increased risk of readmission to the hospital with chest pain
without unequivocal evidence of myocardial infarction (possi-
ble myocardial infarction in the MONICA classification).
Some of these events would be classified clinically as unstable
angina (26). Short-acting calcium antagonists of the dihydro-
pyridine group have been associated with exacerbation of
angina as a result of reflex catecholamine stimulation (14–17).
In the present study, the estimates of risk for readmission with
chest pain, as well as for other adverse outcomes, were highest
with nifedipine, but relatively few patients were given nifedi-
pine, and confidence intervals were wide.
Limitations of the study. The strengths of the present study
include its community-based cohort design, the prospective
definition of end points and the intensive efforts to ascertain all
Table 2. Relative Risks and 95% Confidence Intervals for Each Drug Comparison*
Outcome of Interest
Possible or Definite MI or
Cardiac Death
Definite MI or Cardiac
Death Cardiac Death All-Cause Mortality
End
Point RR (95% CI)
End
Point RR (95% CI)
End
Point RR (95% CI)
End
Point RR (95% CI)
Definite MI
BB (n 5 534) 82 43 1.00 14 1.00 29 1.00
Ca antagonist (n 5 362) 119 1.65 (1.21–2.25) 72 1.52 (1.00–2.29) 39 2.04 (1.05–3.95) 64 1.90 (1.05–3.41)
Neither (n 5 689) 171 1.27 (0.96–1.68) 114 1.46 (1.00–2.13) 74 2.47 (1.32–4.59) 121 2.16 (1.24–3.77)
Both (n 5 270) 79 1.57 (1.13–2.19) 45 1.33 (0.85–2.08) 16 1.30 (0.61–2.77) 28 1.15 (0.58–2.29)
Possible MI
BB (n 5 510) 79 1.00 26 1.00 8 1.00 24 1.00
Ca antagonist (n 5 662) 175 1.45 (1.09–1.92) 69 1.26 (0.78–2.02) 30 1.41 (0.62–3.21) 71 1.44 (0.74–2.82)
Neither (n 5 712) 114 0.94 (0.69–1.27) 57 1.20 (0.73–1.96) 35 1.69 (0.74–3.86) 78 1.61 (0.81–3.19)
Both (n 5 533) 150 1.75 (1.32–2.33) 51 1.58 (0.97–2.58) 13 1.25 (0.50–3.09) 31 1.09 (0.51–2.33)
Definite or possible MI
BB (n 5 1,001) 153 1.00 66 1.00 22 1.00 50 1.00
Ca antagonist (n 5 923) 251 1.50 (1.21–1.87) 119 1.36 (0.98–1.87) 59 1.62 (0.97–2.73) 120 1.67 (1.07–2.60)
Neither (n 5 1,347) 268 1.09 (0.89–1.35) 161 1.36 (1.01–1.85) 103 2.01 (1.23–3.28) 184 1.79 (1.16–2.75)
Both (n 5 711) 193 1.63 (1.30–2.04) 77 1.34 (0.95–1.90) 27 1.33 (0.74–2.38) 52 1.09 (0.65–1.84)
*Results from survival analyses with adjustment for age, gender, hypertension, hypercholesterolemia, diabetes, previous myocardial infarction, angina, stroke,
smoking status, peak creatine kinase level, electrocardiographic code, year of enrollment and use of aspirin, angiotensin-converting enzyme inhibitors, diuretic drugs,
digoxin, antiarrhythmic and bronchodilator medication at hospital discharge. BB 5 beta-blocker; Ca 5 calcium; CI 5 confidence interval; MI 5 myocardial infarction;
RR 5 relative risk.
Table 3. Relative Risks and 95% Confidence Intervals for Calcium Antagonist Use Versus Use of Neither Calcium Antagonists nor
Beta-Adrenergic Blocking Agents*
Outcome of Interest
Possible or Definite MI or
Cardiac Death
Definite MI or Cardiac
Death Cardiac Death All-Cause Mortality
End
Point RR (95% CI)
End
Point RR (95% CI)
End
Point RR (95% CI)
End
Point RR (95% CI)
Neither BBs nor
Ca antagonists (n 5 1,347)
268 1.00 161 1.00 103 1.00 184 1.00
Verapamil (n 5 185) 39 1.21 (0.85–1.73) 17 0.93 (0.55–1.56) 7 0.70 (0.32–1.58) 16 0.90 (0.48–1.70)
Diltiazem (n 5 596) 172 1.43 (1.16–1.77) 86 1.07 (0.81–1.43) 44 0.93 (0.63–1.38) 88 1.00 (0.71–1.41)
Nifedipine (n 5 100) 29 1.66 (1.12–2.47) 14 1.28 (0.73–2.24) 7 1.01 (0.45–2.23) 13 1.08 (0.55–2.10)
All Ca antagonists (n 5 923) 251 1.41 (1.16–1.71) 119 1.03 (0.79–1.34) 59 0.88 (0.62–1.24) 120 0.98 (0.71–1.34)
*Results from survival analyses with adjustment for age, gender, hypertension, hypercholesterolemia, diabetes, previous myocardial infarction, angina, stroke,
smoking status, peak creatine kinase level, electrocardiographic code, year of enrollment and use of aspirin, angiotensin-converting enzyme inhibitors, diuretic drugs,
digoxin, antiarrhythmic and bronchodilator medication at hospital discharge. Abbreviations as in Table 2.
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cases of suspected myocardial infarction and cardiac death and
to document medication use and other important factors
associated with outcome after myocardial infarction. A major
limitation of this observational study relates to the nonrandom
assignment of drug therapy and, consequently, differences in
baseline characteristics among the patients treated with cal-
cium antagonists and beta-blockers (Table 1). Residual con-
founding by indication cannot be excluded as the cause for the
excess risks associated with calcium antagonist use, particularly
when these relative risks were in the range 1 to 2.
Outcome events were identified by repeat registrations of
coronary events and surveillance of death certificates. This
study design may have underestimated the relative risks be-
cause nonfatal cardiac events that occurred in hospitals outside
the study area were not detected. Exposure to drugs after
discharge from the hospital was not assessed and may also have
introduced misclassification. In addition, drug formulation and
dose were not recorded in the MONICA data. Therefore, we
could not evaluate the relative effects of short- and long-acting
calcium antagonists (35). Very few patients in this study were
treated with the newer long-acting calcium antagonists, such as
amlodipine (36) and felodipine.
Underuse of beta-blockers. A noteworthy finding was the
number of patients discharged from the hospital with calcium
antagonists after a suspected myocardial infarction. Almost as
many patients were discharged with calcium antagonists (41%)
as were discharged with beta-blockers (43%). This pattern of
drug use is difficult to understand in the context of trial data
demonstrating unequivocal benefit for beta-blockers after
myocardial infarction (30) and much less benefit for calcium
antagonists (8,11,12). In some cases, drug selection would have
been influenced by contraindications to beta-blockade, but
such contraindications have been estimated to affect no more
than 30% of infarct survivors (34), yet ,50% of patients in this
cohort left the hospital with beta-blockers. Underuse of beta-
blockers has been reported in several other studies (34,37,38),
but the reasons for these apparently suboptimal prescribing
patterns are poorly understood (37,39).
Conclusions. The present results are consistent with ran-
domized trial data showing benefit from beta-blockers after
myocardial infarction and no effect on the risk of myocardial
infarction and death with the use of calcium antagonists. These
results confirm that whenever possible, beta-blockers should
be used in preference to calcium antagonists in patients with a
myocardial infarction.
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